



MEDIMETRIKS
PHARMACEUTICALS, INC.

Corporate Overview

Experts in Maximizing Value in Dermatology

- **Commercial dermatology and podiatry company with proven expertise in maximizing brands**
 - Commercialization strength anchored by more than 30 years of experience & relationships in Dermatology and Podiatry
 - Marketed brands for the most common diseases in Dermatology and Podiatry with wide breadth and depth across these markets
- **Dedicated management team with a proven track record of generating sales and increasing profits**
 - Proven M&A track record of value creation, including acquisition, development and divestment of two significant dermatology value drivers, Xepi (ozenoxacin cream) sold to Biofrontera and MM36 (difamilast) sold to Acrotech Biopharma
 - Experience in leading, managing and financing a public company
 - Bradley Glassman, President and CEO  [BRADLEY PHARMACEUTICALS, INC.](#)
 - Alan Goldstein, Executive VP, Business Development  [BRADLEY PHARMACEUTICALS, INC.](#)
 - Brent Lenczycki, Chief Financial Officer  [BRADLEY PHARMACEUTICALS, INC.](#)
 - David Addis, Chief Operating Officer  [BRADLEY PHARMACEUTICALS, INC.](#)
 - Donna Heren, VP, Regulatory Affairs & Quality Assurance  [BRADLEY PHARMACEUTICALS, INC.](#)

POISED FOR GROWTH

1 Strong Commercial Platform

Foundation for Growth Through Licensing and Acquisition

- Commercial experts in maximizing brand value in key medical dermatology markets
- Robust portfolio of brands promoted through experienced national sales force
 - Dedicated, growing field force growing to 30 professional sales representatives that support the highest potential markets in U.S.
- Senior Management has strong, long-standing relationships with dermatology Key Opinion Leaders & High Volume Prescribers

2 Lifecycle Management & Development Expertise

Development Capabilities Support Lifecycle Management Strategy

- Significant lifecycle management and line extension opportunities exist in the current brand portfolio
- Authorized Generic opportunity on many of existing brands offers incremental and diverse revenue potential

3 Transaction/M&A Expertise

History of Value Creating Transactions

- Capital raised of \$20MM+ and more than \$300MM in transactions
- Executed 40+ corporate transactions including:
 - Licensing of Ozenoxacin cream from Ferrer, achieving FDA approval of Xepi™ (ozenoxacin) cream and divestment to Cutanea Life Sciences in March 2018
 - Licensing of MM36 (difamilast) from Otsuka Pharmaceutical, leading the U.S. program through Phase 2, and divestment to Acrotech Biopharma in December 2021

CORE BRAND GROWTH DRIVERS

- Marketed brands for the treatment of common Dermatology diseases, including acne, rosacea, psoriasis, atopic dermatitis & nail dystrophy

SKIN & SCALP DERMATOSES	
Clodan[®]	(clobetasol propionate)
Ketodan[®]	(ketoconazole foam)
NEO-SYNALAR[®]	(fluocinolone acetonide/neomycin)
SYNALAR[®]	(fluocinolone acetonide)
Tovet[™]	(clobetasol foam)
ONYCHODYSTROPHY	
Genadur[®]	(hydrosoluble nail lacquer)

ACNE & ROSACEA	
Clindacin[®]	(clindamycin phosphate)
Neuac[®]	(clindamycin/benzoyl peroxide)
Sumadan[®]	(sodium sulfacetamide/sulfur)
INFLAMMATORY SKIN CONDITIONS	
NICADAN[®]	(niacinamide)